Related Experiment Video
Updated: Jun 18, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
Published on: April 29, 2014
What is new in kidney cancer?
1Dokuz Eylul University, School of Medicine, Department of Urology, Izmir, Turkey. ziya.kirkali@gmail.com
Targeted therapies have advanced renal cell carcinoma (RCC) treatment, with six agents now approved for metastatic disease. Recent congresses highlight new developments in this key area of urologic oncology.
Area of Science:
- Urologic oncology
- Medical oncology
Background:
- Renal cell carcinoma (RCC) is a significant focus in urologic oncology.
- Advances in understanding disease mechanisms have driven the development of targeted therapies.
- Six targeted therapy agents are currently approved for metastatic RCC treatment.
Purpose of the Study:
- To highlight key presentations on renal cell carcinoma from the Joint 15th European Cancer Organisation (ECCO) - 34th European Society of Medical Oncology (ESMO) Multidisciplinary Congress.
- To provide an overview of recent advancements in metastatic renal cell carcinoma treatment.
Main Methods:
- Review of presentations from the ECCO-ESMO Multidisciplinary Congress.
- Synthesis of information on targeted therapies for renal cell carcinoma.
Main Results:
- The congress showcased new information regarding the treatment of metastatic renal cell carcinoma.
- The field of targeted therapies for RCC continues to evolve.
Conclusions:
- Recent congresses underscore the dynamic progress in managing metastatic renal cell carcinoma.
- Continued research and development are crucial for improving patient outcomes in RCC.
Related Concept Videos
Kidney Transplant I: Introduction
Kidney Transplant III: Nursing Management
Kidney Transplant II: Surgical Procedure
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Chronic Kidney Disease I: Introduction
Nephrons

